| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 55513-0132-21 | 55513-0132 | trastuzumab-anns | Kanjinti | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jul 1, 2025 | In Use | |
| 50242-0070-86 | 50242-0070 | Obinutuzumab | Gazyva | 1000.0 mg/40mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Nov 4, 2013 | In Use | |
| 55513-0956-21 | 55513-0956 | Panitumumab | Vectibix | 400.0 mg/20mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 1, 2025 | In Use | |
| 50242-0061-01 | 50242-0061 | Bevacizumab | Avastin | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Feb 26, 2004 | In Use | |
| 50242-0108-86 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 23, 2017 | In Use | |
| 00173-0808-02 | 00173-0808 | Ofatumumab | Arzerra | Immunotherapy | Monoclonal Antibody | CD20 | Oct 26, 2009 | Mar 31, 2012 | No Longer Used | ||
| 50242-0060-10 | 50242-0060 | Bevacizumab | Avastin | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Apr 1, 2019 | Jan 31, 2023 | In Use |
| 00173-0808-01 | 00173-0808 | Ofatumumab | Arzerra | Immunotherapy | Monoclonal Antibody | CD20 | Oct 26, 2009 | Mar 31, 2012 | No Longer Used | ||
| 55513-0730-01 | 55513-0730 | Denosumab | XGEVA | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Nov 18, 2010 | In Use | |
| 55513-0206-01 | 55513-0206 | Bevacizumab-awwb | MVASI | 100.0 mg/4mL, 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 1, 2018 | In Use | |
| 00469-3425-10 | 00469-3425 | ZOLBETUXIMAB | VYLOY | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CLDN18.2 | Intravenous | Oct 24, 2024 | In Use | |
| 63459-0305-47 | 63459-0305 | TRASTUZUMAB | HERZUMA | Immunotherapy | Monoclonal Antibody | HER2 | Mar 16, 2020 | In Use | |||
| 00002-7669-01 | 00002-7669 | Ramucirumab | Cyramza | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Apr 21, 2014 | In Use | |
| 72606-0059-01 | 72606-0059 | Denosumab-bmwo | Denosumab-BMWO | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Sep 10, 2025 | In Use | |
| 50881-0013-03 | 50881-0013 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | In Use | |
| 55513-0955-01 | 55513-0955 | Panitumumab | Vectibix | 200.0 mg/10mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 10, 2006 | Feb 28, 2010 | No Longer Used |
| 55513-0206-21 | 55513-0206 | Bevacizumab-awwb | MVASI | 100.0 mg/4mL, 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 27, 2025 | In Use | |
| 00143-9166-01 | 00143-9166 | Denosumab-qbde | XTRENBO | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jan 8, 2026 | In Use | |
| 50242-0260-86 | 50242-0260 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | May 3, 2021 | In Use | |
| 50242-0159-01 | 50242-0159 | Mosunetuzumab | Lunsumio | 1.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | Dec 22, 2022 | In Use | |
| 00173-0821-33 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 22, 2011 | Aug 31, 2017 | No Longer Used |
| 55513-0207-21 | 55513-0207 | Bevacizumab-awwb | MVASI | 400.0 mg/16mL, 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 27, 2025 | In Use | |
| 00069-0305-01 | 00069-0305 | Trastuzumab-qyyp | Trazimera | 420.0 mg/20 mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Feb 24, 2020 | In Use | |
| 55513-0710-01 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 5, 2010 | In Use | |
| 82143-0001-01 | 82143-0001 | Bevacizumab | Avzivi | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan 1, 2025 | In Use |
Found 12159 results — Export these results
Home